Breast cancer chemoprevention

Oncology Reviews

Volumn 2, Issue 4, 2008, Pages 223-228

  Sestak, Ivana ^a   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention; Selective oestrogen receptor modulators

Indexed keywords

EID: 84870514088     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0078-9     Document Type: Review

References (45)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
2. Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356:2388-2398 (Pubitemid 46883773)
3. Tseng M, Weinberg CR, Umbach DM et al (1999) Calculation of population attributable risk for alcohol and breast cancer (United States). Cancer Causes Control 1999;10:119-123 (Pubitemid 29161103)
4. Wiseman H (1994) Tamoxifen: Molecular basis of use in cancer treatment and prevention. 1st ed. 1994, Chichester: John Wiley & Sons Ltd
5. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467
6. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300 (Pubitemid 36126189)
7. Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet 2:282 (Pubitemid 15047587)
8. Jordan C (1990) Tamoxifen for the prevention of breast cancer, De Vita, Editor Cancer Prevention 1-12
9. Cuzick J, Wang DY, Bulbrook RD (1986) The prevention of breast cancer. Lancet 1:83-86 (Pubitemid 16182901)
10. Powles T, R. Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101 (Pubitemid 28321321)
11. Powles TJ Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283-290 (Pubitemid 47073491)
12. Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817-824 (Pubitemid 35257944)
13. Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282 (Pubitemid 47073490)
14. Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727-737 (Pubitemid 47073533)
15. Veronesi U, Maisonneuve P, Sacchini V et al (2002) Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124 (Pubitemid 34270739)
16. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652-1662 (Pubitemid 41672231)
17. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388 (Pubitemid 28439961)
18. Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97 (Pubitemid 28321320)
19. Freedman AN, Graubard BI, Rao SR et al (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95:526-532 (Pubitemid 36511623)
20. Gail MH, Costantino JP, Bryant J, et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846
21. Hershman D, Sundararajan V, Jacobson JS et al (2002) Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 20:9-16 (Pubitemid 34032590)
22. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197 (Pubitemid 29275701)
23. Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761 (Pubitemid 39654569)
24. Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137 (Pubitemid 44050394)
25. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. Jama 295:2727-2741
26. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139 (Pubitemid 34694019)
27. Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147 (Pubitemid 46224022)
28. Coates AS, Keshaviah A, Thurlimann B, et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492 (Pubitemid 350002953)
29. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092 (Pubitemid 38298988)
30. Goss PE, Ingle JN, Martino S, et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802 (Pubitemid 37362955)
31. Jakesz R, Jonat W, Gnant M, et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462 (Pubitemid 41111693)
32. Mamounas E, Jeong J-H, Wickerham DL et al (2006) Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): Intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100[Suppl1]:S22
33. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810 (Pubitemid 37310221)
34. Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
35. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
36. Rahme E, Ghosn J, Dasgupta K et al (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159
37. Swede H, Mirand AL, Menezes RJ et al (2005) Association of regular aspirin use and breast cancer risk. Oncology 68:40-47 (Pubitemid 40675007)
38. Kwan ML, Habel LA, Flick ED et al (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573-579 (Pubitemid 351698864)
39. Mazhar D, Ang R, J. Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94:346-350 (Pubitemid 43237558)
40. Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27
41. Gierach GL, Lacey JV Jr, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38
42. Wu K, Zhang Y, Xu XC et al (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62:6376-6380 (Pubitemid 35364089)
43. Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98:700-707 (Pubitemid 43821787)
44. Eliassen AH, Colditz GA, Rosner B et al (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264-2271 (Pubitemid 41549923)
45. Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139 (Pubitemid 351480564)